Skip to main content
. Author manuscript; available in PMC: 2021 Apr 2.
Published in final edited form as: Clin Rev Allergy Immunol. 2020 Nov 13;60(1):31–45. doi: 10.1007/s12016-020-08823-4

Table 1.

Biologics and small molecule drugs targeting the IL-23/IL-17 axis approved by FDA to treat patients with rheumatic diseases

Medication Target Indication
Secukinumab (Novartis) IL-17A Plaque psoriasis
Psoriatic arthritis
Ankvlosing spondylitis
lxekizumab (Lilly) IL-17A Plaque psoriasis
Psoriatic arthritis
Psoriatic arthritis
Brodalumab (AstraZeneca) IL-17RA Plaque psoriasis
Ustekinumab (Janssen) IL-12 and IL-23 Plaque psoriasis
Psoriatic arthritis
Guselkumab (Janssen) IL-23 Plaque psoriasis
Psoriatic arthritis
Risankizumab (AbbVie) IL-23 Plaque psoriasis
Tildrakizumab (Sun Pharmaceuticals) IL-23 Plaque psoriasis
Tofacitinib (Novartis) JAK.l, JAK3 and a lesser degree JAK2 Psoriatic arthritis
Rheumatoid arthritis
Baricitinib (Eli Lilly) JAK1 and JAK2 Rheumatoid arthritis
Upadacitinib (AbbVie) JAK1 Rheumatoid arthritis